The therapeutic potential of agents acting via purine receptors

Bibliography

• BURNSTOCK G: A basis for distinguishing two types ofpurinergic receptors. In: Cell Membrane Receptors for Drugs and Hormones: A Multidisciplinary Approach. Boils L, Straub RW (Eds.), Raven Press, New York (1978):10–18.
   Google Scholar
• VAN CALKER D, MULLER M, HAMPRECHT B: Adenosineregulates via two different types of receptors, the accu-mulation of cyclic AMP in cultured brain cells J Neuro-chem. (1979) 33:999–1005
   Google Scholar
• LINDEN JL, JACOBSON MA, HUTCHINS C, WILLIAMS M:In: Handbook of Receptors and Channels. Volume 1: G-protein coupled receptors. Peroutka SJ (Ed.), CRC Press, Boca Raton (1994):29–44.
   Google Scholar
• STILES G: Adenosine receptors. J. Biol. Chem. (1992)267:6451–6454.
   PubMed Web of Science ®Google Scholar
• COOPER DMF, CALDWELL KK: Signal transductionmechanisms for adenosine. In: Adenosine and adeno-sine receptors. Williams M (Ed.), Humana, Clifton, NJ, USA (1990):105–41.
   Google Scholar
• FREDHOLM BB, ABBRACCHIO MP, BURNSTOCK G et al.:Towards a revised nomenclature for P1 and P2 recep-tors. TIPS (1997) 18:79–82.
   PubMed Web of Science ®Google Scholar
• WEISMAN GA, TURNER JT, FEDAN JS: Structure and func-tion of P2 purinoceptors. JPET (1996) 277 :1–9.
   PubMed Web of Science ®Google Scholar
• SKLADANOWSKI AC, NEWBY AC: 5'-nucleotidases in-volved in adenosine formation. In: Role of Adenosine and Adenine Nucleotides in the Biological System. Imai S, Nakazawa M (Eds.), Elsevier Science, Amsterdam, The Neth-erlands (1991):289–300.
   Google Scholar
• MOSER GH, SCHRADER J, DEUSSEN A: Turnover of adenosine in plasma of human and dog blood. Arm J Physiol. (1989) 256:C799–806.
   PubMed Web of Science ®Google Scholar
• BELT JA, MARINA NM, PHELPS DA, CRAWFORD CR: Nu-cleoside transport in normal and neoplastic cells. Adv. Enzyme. Regul. (1993) 33:235–252.
   PubMedGoogle Scholar
• DRURY AN, SZENT-GYORGI A: The physiological activ-ity of adenine compounds with special reference to their action upon the mammalian heart. J. Physiol. (Lond) (1929) 68:213–237.
   Google Scholar
• BELARDINELLI L, LINDEN J, BERNE RM: The cardiac ef-fects of adenosine. Prog. Cardiovasc.Dis. (1989) 22:73–97.
   Web of Science ®Google Scholar
• ORTWINE DF, BRIDGES AJ, HUMBLET C, TRIVEDI BK: Adenosine agonists. Characterization of the N6-region of the adenosine A2 receptor via molecular modeling techniques. In: Purines in Cellular Signaling Targets for New Drugs. Jacobson KA, Daly JW, Manganiello V (Eds.), Springer Verlag, New York, USA (1990):152–157.
   Google Scholar
• PATEL M, SHEEHAN MJ, STRON P: Failure of CGS15943 A to block the hypotensive action of agonists acting at the adenosine A3 receptor. Br. J Pharmacol. (1994) 113:741–748.
   PubMed Web of Science ®Google Scholar
• HANNON JP, PFANNKUCHE HJ, FOZARD JR: A role formast cells in adenosine A3 receptor-mediated hypoten-sion in the rat. Br. J Pharmacol. (1995) 115:945–952.
   PubMed Web of Science ®Google Scholar
• SHEPHERD RK, LINDEN J, DULING BR: Adenosine-mediated vasoconstriction in vivo. Role of the mast cell and A3 adenosine receptor. Circ. Res. (1996) 78:627–34.
   Google Scholar
• CLEMO HF, BELARDINELLI L: Effect of adenosine on atrioventricular conduction. I. Site and characteriza-tion of adenosine action in the guinea pig atrioven-tricular node. Circ. Res. (1986) 59:427–36.
   Google Scholar
• DENNIS DM, RAATIKAINEN MJ, MARTENS JR, BELARDI-NELLI L: Modulation of atrioventricular nodal function by metabolic and allosteric regulators of endogenous adenosine in guinea pig heart. Circulation. (1996) 94:2551–2559.
   PubMed Web of Science ®Google Scholar
• BERNE RM: Cardiac nucleosides in hypoxia: possible role in regulation of coronary flow. J Physiol. (Lond) (1963) 204:317–322.
   Google Scholar
• YAO Z, GROSS GJ: Glibenclamide antagonizes adeno-sine Ai receptor-mediated cardioprotection in stunned canine myo car dium. Circulation (1993) 88:235–44.
   PubMed Web of Science ®Google Scholar
• LIU GS, RICHARDS SC, OLSSON RA et al: Evidence that the adenosine A3 receptor may mediate the protection afforded by preconditioning in the isolated rabbit heart. Cardiovasc. Res. (1994) 28:1057–1061.
   PubMed Web of Science ®Google Scholar
• ARMSTRONG S, GANOTE CE: Adenosine receptor speci-ficity in preconditioning of isolated rabbit cardiomyo-cytes: evidence of A3 receptor involvement. Cardiovasc. Res. (1994) 28:1049–1056.
   PubMed Web of Science ®Google Scholar
• ZHAO ZQ, NAKANISHI K, MCGEE DS et al.: Ai receptor mediated myocardial infarct size reduction by endoge-nous adenosine is exerted primarily during ischae-mia. Cardiovasc. Res. (1994) 28:270–279.
   PubMed Web of Science ®Google Scholar
• TRACEY WR, MAGEE W, MASAMUNE H et al.: Selectiveadenosine A3 receptor stimulation reduces ischemic myocardial injury in the rabbit heart. Cardiovasc. Res. (1997) 33:410–415.
   PubMed Web of Science ®Google Scholar
• ROMSON JL, HOOK BG, KUNKEL SL et al.: Reduction ofthe extent of myocardial injury by neutrophil deple-tion in the dog. Circulation (1983) 67:1016–1023.
   PubMed Web of Science ®Google Scholar
• SIMPSON PJ, FANTONE JC, LUCCHESI BR: Myocardialischemia and reperfusion injury: oxygen radicals and the role of the neutrophil. In: Oxygen Radicals and Tissue Injury: Proceedings of an Upjohn Symposium. Federation of American Societies for Experimental Biology Bethesda, MD, USA (1988):63–77.
   Google Scholar
• WALKER DM, YELLON DM: Ischaemic preconditioning:from mechanisms to exploitation. Cardiovasc. Res. (1992) 26:734–739.
   PubMed Web of Science ®Google Scholar
• DOWNEY JM, LIU GS, THORNTON JD: Adenosine andthe anti-infarct effects of preconditioning. Cardiovasc. Res. (1993) 27:3–8.
   PubMed Web of Science ®Google Scholar
• LEESAR MA, STODDARD M, AHMED M et al.: Precondi-tioning of human myocardium with adenosine during coronary angioplasty. Circulation (1997) 95:2500–2507.
   PubMed Web of Science ®Google Scholar
• WANG J, DRAKE L, SAJJADI F et al.: Dual activation ofadenosine Ai and A3 receptors mediates precondition-ing of isolated cardiac myocytes. Eur. j Pharmacol. (1997) 320:241–248.
   PubMed Web of Science ®Google Scholar
• HOURANI SMO, CUSACK NJ: Pharmacological receptorson blood platelets. Pharm. Rev. (1991) 43:243–298.
   PubMed Web of Science ®Google Scholar
• SAVI P, COMBALBERT J, GAICH C et al:The an tiaggr egat-ing activity of clopidogrel is due to a metabolic activa-tion by the hepatic cytochrome P450-1a. Thromb. Haemost. (1994) 72:313–317.
   PubMed Web of Science ®Google Scholar
• HALL JE, GRANGER JP, HESTER RL: Interactions betweenadenosine and angiotensin II in controlling glomeru-lar filtration. Am.J. Physiol. (1985) 248:F340–6.
   PubMedGoogle Scholar
• BARONE S, CHURCHILL PC, JACOBSON KA: Adenosinereceptor prodrugs: towards kidney-selective dialkylx - anthines. JPET (1989) 250:79–85.
   PubMed Web of Science ®Google Scholar
• RANDLE PJ, GARLAND PB, HALES LN, NEWSHOLME EA: The glucose fatty acid cycle, its role in insulin sensitiv-ity and the metabolic disturbances of diabetes melli-tus. Lancet (1963) 1:785–789.
   PubMed Web of Science ®Google Scholar
• HESELTINE L, WEBSTER JM, TAYLOR R: Adenosine ef-fects upon insulin action on lipolysis and glucose transport in human adipocytes. Mo/. Cell. Biochem. (1995) 144:147–151.
   PubMed Web of Science ®Google Scholar
• FOSTER AC, MILLER, LP, WIESNER JB: Regulation of en-dogenous adenosine levels in the CNS: potential for therapy in stroke, epilepsy and pain. In: Purine and Pyrmidine Metabolism in Man VIII. Sahota A, Taylor M (Eds.), Plenum Press, New York, USA (1995):427–430.
   Google Scholar
• DUNWIDDIE T: The physiological role of adenosine inthe central nervous system. mt. Rev. Neurobiol. (1985) 27:63–139
   PubMed Web of Science ®Google Scholar
• JARVIS MF, WILLIAMS M: Adenosine in central nervoussystem function. Adenosine and adenosine receptors. Williams M (Ed.) Humana Press, (1990):423–474.
   Google Scholar
• PORKKA-HEISKANEN T, STRECKER RE, THAKKAR M eta].:Adenosine: a mediator of the sleep-inducing effects of prolonged wakefulness. Science (1997) 276:1265–1268.
   Google Scholar
• WILLIAMS M: Purine nucleosides and nucleotides as central nervous system modulators. Ann. NY Acad. Sci. (1990) 603:93–107.
   PubMed Web of Science ®Google Scholar
• SAJJADI FG, TAKABAYASHI K, FOSTER AC et al.: Inhibi-tion of TNE-13 expression by adenosine. j immuna (1996) 3435–3442.
   PubMedGoogle Scholar
• BOUMA MG, JEUNHOMME TM, BOYLE DL eta].: Adeno-sine inhibits neutrophil degranulation in activated hu-man whole blood: involvement of adenosine A2 and A3 receptors. j immuna (1997) 158:5400–5408.
   Google Scholar
• BARNES PJ: Molecular mechanisms of antiasthma ther-apy. Ann. Med. (1995) 27:531–535.
   PubMed Web of Science ®Google Scholar
• WALKER BA, JACOBSON MA, KNIGHT DA et al.: Adeno-sine A3 receptor expression and function in eosino-phils. Am. j Respir. Cell Ma Biol. (1997) 16:531–537.
   PubMed Web of Science ®Google Scholar
• NYCE JW, METZGER WJ: DNA antisense therapy for asthma in an animal model. Nature (1997) 385 :721–725.
   PubMed Web of Science ®Google Scholar
• WILLIAMS M, BHAGWAT SS: P2 purinoceptors: a family of novel therapeutic targets. In: Annual Reports In Me-dicinal Chemistry. Bristol JA (Ed.), Academic Press Univ. (1996) 31 :31–41.
   Google Scholar
• JACOBSON KA, TRIVEDI BK, CHURCHILL PC, WILLIAMS M: Novel therapeutics acting viapurine receptors. Bio-chemical Pharmacology (1991) 41:1399–1410.
   PubMed Web of Science ®Google Scholar
• HAMILTON HW, HAWKINS LD, PATT WC eta].: Abstract presented to the division of medicinal chemistry at the 196th National ACS Meeting. (1988). Abstract 80.
   Google Scholar
• BRUNS RF, GERGUS JH: Allosteric enhancement of adenosine Ai receptor binding and function by 2-amino-3-benzoylthiophenes. Mol. Pharmacol. (1990) 38:939–949.
   PubMed Web of Science ®Google Scholar
• BRUNS RF, FERGUS JH, COUGHENOUR LL et aL: Structure-activity relationships for enhancement of adenosine Ai receptor binding by 2-amino-3-benzoylthiophenes. Mol. Pharmacol. (1990) 38:950–958.
   PubMed Web of Science ®Google Scholar
• NORTON ED, JACKSON EK, TURNER MB eta].: The effects of intravenous infusions of selective adenosine Ai-r-eceptor and A2-receptor agonists on myocardial reper-fusion injury. Am. Heart J. (1992) 123:332–328.
   Google Scholar
• NORTON ED, JACKSON EK, VIRMANI R, FORMAN MB: H-feet of intravenous adenosine on myocardial reperfu-sion injury in a model with low myocardial collateral blood flow. Am. Heart] (1991) 122:1283–1291.
   PubMed Web of Science ®Google Scholar
• VAN WINKLE DM, CHIEN GL, WOLFF RA eta].: Car diopro-tection provided by adenosine receptor activation is abolished by blockade of the KATP channel. Am. J. Physiol. (1994) 266:H829–39.
   Google Scholar
• SANDHU GS, BURRIER AC, JANERO DR: Adenosine de-aminase inhibitors attenuate ischemic injury and preserve energy balance in isolated guinea pig heart. Am. J. Physiol. (1993) 265 :H1249–56.
   PubMed Web of Science ®Google Scholar
• TOOMBS CF, MCGEE S, JOHNSTON WE, VINTEN-JOHANSEN J: Myocardial protective effects of adeno-sine. Infarct size reduction with pretreatment and con-tinued receptor stimulation during ischemia. Circulation (1992) 86:986–994.
   Google Scholar
• YAO Z, GROSS GJ: A comparison of adenosine-inducedcardioprotection and ischemic preconditioning in dogs. Efficacy, time course, and role of KATP channels. Circulation (1994) 89:1229–1236.
   Google Scholar
• ZUGHAIB ME, ABD-ELFATTAH AS, JEROUDI MO et al.:Augmentation of endogenous adenosine attenuates myocardial 'stunning' independently of coronary flow or hemodynamic effects. Circuiation (1993) 88:2359–2369.
   PubMed Web of Science ®Google Scholar
• DORHEIM TA, HOFFMAN A, VAN WYLEN DG, MENTZER RM, Jr.: Enhanced interstitial fluid adenosine attenu-ates myocardial stunning. Surgery (1991) 110:136–145.
   Google Scholar
• VAN BELLE H: Nucleoside transport inhibition: a thera-peutic approach to cardioprotection via adenosine? Cardiovasc. Res. (1993) 27:68–76.
   Google Scholar
• GRIFFITH MJ, LINKER NJ, GARRATT CJ eta].: Relative effi-cacy and safety of intravenous drugs for termination of sustained ventricular tachycardia. Lancet (1990) 336:670–673.
   Google Scholar
• VERANI MS, MAHMANIAN JJ, HIXSON JB eta].: Diagnosisof coronary artery disease by controlled coronary vasodialation with adenosine and thallium-201 in pa-tients unable to exercise. Circa/at/on (1990) 82:80–87.
   Google Scholar
• FULLERTON DA, JONES SD, GROVER FL, MCINTYRE RC,Jr.: Adenosine effectively controls pulmonary hyper-tension after cardiac operations. Ann. Thorac. Surg. (1996) 61:1118–1123.
   Google Scholar
• SEGERDAYL M, EKBLOM A, SOLLEVI A: The influence of adenosine, ketamine, and morphine on experimen-tally induced ischemic pain in healthy volunteers. An-esth. Analg. (1994) 79:781–791.
   Google Scholar
• SYLVEN C, ERIKSSON B, JENSEN J et al: Analgesic effects of adenosine during exercise-provoked myocardial is-chaemia. Neuroreport (1996) 7:1521–1525.
   PubMed Web of Science ®Google Scholar
• WEINBERGER M, HENDELES L: Theophylline in asthma. New Engl. J. Med. (1996) 334:1380–1388.
   PubMed Web of Science ®Google Scholar
• MACLEOD D, DJUKANOVIC R:. Low-dose theophylline: a new anti-inflammatory role in asthma management? Monaldi. Arch. Chest. Dis (1996) 51:30–34.
   Google Scholar
• HERAS M, CHESEBRO JH, FUSTER V et al.: High risk of thromboemboli early after bioprosthetic cardiac valve replacement. j Am. Coll. Cardio]. (1995) 25:1111–1119.
   PubMed Web of Science ®Google Scholar
• BROWN KA: Prognostic value of thallium-201 myocar-dial perfusion imaging. a diagnostic tool comes of age. Circulation (1991) 83:363–381.
   PubMed Web of Science ®Google Scholar
• CADROY Y, HARKER LA: Platelets, and antithrombotic therapies. In: Cardiovascular Pharmacology Ord Edition). Anonaccio M (Ed.), Raven Press, NY, USA (1990):515–539
   Google Scholar
• Sanofi Plavix indication should reflect CAPRIE patient population - FDA committee; single trial sufficient to suffport effeicacy in atherothrombotic event preven-tion. FDC Reports (1997) 59 (44) :11–12.
   Google Scholar
• SPEDDING M, WILLIAMS M: Developments in purine and pyrimidine receptor-based therapeutics. Drug Dev. Res. (1996) 39:436–441.
   Web of Science ®Google Scholar
• Pharmaprojects. PJB Publications Ltd., Richmond, Surrey UK.
   Google Scholar
• WAGNER H, HILAVEC-KRIZMAN M, GADIENT F et al.: Species-dependent cardiovascular effects of SDZ-WAG-994, a selective adenosine Ai receptor agonist. Br. J. Pharmacol. (1994) 112 (Suppl.):Abst 402P.
   Google Scholar
• WAGNER H et al.: The pharmacological properties of SDZ WAG 994, a potent, selective and orally active adenosine Ai receptor agonist. Drug. Develop. Res. (1994) 31 :Abst. 1229.
   Google Scholar
• FOZARD JR et al.: Cardiovascular and metabolic effects of SDZ WAG 994, a selective adenosine Ai receptor ago-nist, after acute and chronic dosing in the rhesus mon-key. Brit. J. Pharmacol. (1994) 112 (Suppl.):Abst. 134P.
   Google Scholar
• BELL PA et al.: Effects of WAG 994 on lipid and glucose metabolism in vitro and in vivo. Diabetes (1994) 43 (Suppl. 1):Abst. 135.
   Google Scholar
• DEEMS RO et al.: Effects of the antilipolytic agent WAG 994 on glucose metabolism in normal rats. Diabetes (1994) 43 (Suppl. 1):Abst. 139.
   Google Scholar
• ISHIKAWA J, MITANI M, BANDOH T eta].: Hypoglycemic and hypotensive effects of an adenosine Ai receptor agonist in SHR in complications with hyperglycemia. Jpn. j Pharmacol. (1995) 67 (Suppl. 1):1–71.
   Google Scholar
• BELARDINELLI L, JIYUAN L, DENNIS D eta].: The cardiac effects of a novel Ai-adenosine receptor agonist in guinea pig isolated heart. JPET (1994) 271:1371–1382.
   Google Scholar
• ANAND I, CHANDRASHESKHAR Y, MCCAULEY A et al.:Cardiovascular and neurohormonal effects of SDZ-WAG-994, a selective adenosine Ai receptor agonist, in man. J. Am. Coll. Cardiol (1995) February Special Issue 723–724.
   Google Scholar
• PEPINE CJ, ANAND IS, BERTOLET BD eta].: Neur ohormo-nal and hemodynamic effects of SDZ-WAG-994 a novel selective Ai adenosine receptor agonist in patients with heart failure. J Am. Coll. Cardiol. (1995) February Special Issue 958–964.
   Google Scholar
• SDZ-WAG-994 Clin. Trials. Monitor (1995) 48:36.
   Google Scholar
• STRONG P, ANDERSON R, COATES J eta].: Suppression of non-esterified fatty acids and triacylglycerol in experi-mental animals by the adenosine analogue GR79236. Clin. Sci. (1 993) 84:663–669.
   Google Scholar
• GARDNER CJ, TWISSELL DJ, COATES J, STRONG P: The ef-fects of GR79236 on plasma fatty acid concentrations, heart rate and blood pressure in the conscious rat. Eur. Pharm. (1994) 257:117–121.
   PubMed Web of Science ®Google Scholar
• THOMPSON CS, STRONG P, MIKHAILIDIS DP: Improve-ments of ketoacidosis in the diabetic rat after the administration of the oral antilipolytic agent GR79236. Clin. Sci. (1994) 86:593–598.
   PubMed Web of Science ®Google Scholar
• MERKEL LA, HAWKINS ED, COLUSSI DJ et al.: Cardiovas-cular and antilipolytic effects of the adenosine agonist GR79236. Pharmacology (1995) 51:224–236.
   PubMed Web of Science ®Google Scholar
• WILLIAMS M: Purinocep tor targeted therapeutics: to-wards selective agents for unmet medical needs. Phar-macol. Res. (1995) 31:166.
   Google Scholar
• KNUTSEN US, LAU J, THOMSEN C eta].: Promising anti-convulsant and antiischemic effects of new, selective adenosine agonists in animal models. Am. Coll. (1994)49.
   Google Scholar
• SHIMADA J, SUZUKI F, NONAKA H, ISHII A: 8 - Polycycloalky1-1,3-dipropylx anthines as potent and selective antagonists for Ai-adenosine receptors. J Med. Chem. (1992) 35:924–930.
   PubMed Web of Science ®Google Scholar
• MIZUMOTO H, KARASAWA A, KUBO K: Diuretic and re-nal protective effects of 8-(noradamantan-3-y1)-1,3-dipropylxanthine (KW-3902), a novel adenosine Al-receptor antagonist, via pertussis toxin insensitive mechanism. J Pharmacol. Exp. Ther. (1993)266:200–206.
   PubMed Web of Science ®Google Scholar
• KOBAYASHI T, MIZUMOTO H, KARASAWA A: Diuretic ef-fects of KW-3902 (8-(noradamantan-3-y1)-1,3-dipropylxanthine), a novel adenosine Al receptor an-tagonist, in conscious dogs. Biol. Pharm. Bull. (1993) 16:1231–1235.
   PubMed Web of Science ®Google Scholar
• KUSAKA H, KARASAWA A: Effects of repeated admini-stration of KW-3902, a novel adenosine Ai receptor an-tagonist, on its pharmacological actions. Jpn. J. Pharmacol. (1993) 63:513–519.
   PubMedGoogle Scholar
• MIZUMOTO H, KARASAWA A: Effects of adenosine Aiagonist and antagonist on urinary volume and Na ex-cretion in IAP-treated and non-treated rats. Jpn. j Phar-macol. (1993) 63:257–259.
   PubMedGoogle Scholar
• YAO K, KUSAKA H, SATO K, KARASAWA A: Protective ef-fects of KW-3902, a novel adenosine Ai receptor an-tagonist, against gentamicin-induced acute renal failure in rats. Jpn. j Pharmacol. (1994) 65:167–170.
   PubMedGoogle Scholar
• YAO K, KUSAKA H, SANO J, SATO K, KARASAWA A: Diu-retic effects of KW-3902, a novel adenosine Ai receptor antagonist, in various models of acute renal failure in rats. Jpn. j Pharmacol. (1994) 64:281–288.
   PubMedGoogle Scholar
• NAGASHIMA K, KUSAKA H, SATO K, KARASAWA A: H-fects of KW-3902, a novel adenosine Ai receptor an-tagonist, on cephaloridine-induced acute renal failure in rats. Jpn. j Pharmacol. (1994) 64:9–17.
   PubMedGoogle Scholar
• YAMAGATA T, KOBAYASHI T, KUSAKA H, KARASAWA A: Diuretic effects of KW-3902, a novel adenosine Al-receptor antagonist, in anesthetized dogs. Biol. Pharm. Bull. (1994) 7:1599–1603.
   Google Scholar
• NAGASHIMA K, KUSAKA H, KARASAWA A: Protective ef-fects of KW-3902, an adenosine Al-receptor antago-nist, against cisplatin-induced acute renal failure in rats. jpn.J. Pharmacol. (1995) 67:349–357.
   PubMedGoogle Scholar
• MIZUMOTO H, KARASAWA A: Renal tubular site of ac-tion of KW-3902, a novel adenosine A 1 receptor antagonist, in anesthetized rats. Jpn. j Pharmacol (1993) 61:251–253.
   PubMedGoogle Scholar
• MAY JM eta].: N-0861 : a selective Ai adenosine receptor antagonist. FASEB J (1991) 5 (6):Abst. 6971.
   Google Scholar
• MARTIN PL, CUSACK NJ: Halogen substituted N6-endonorborny1-9-methyladenines are potent and se-lective Ai adenosine receptor antagonists. Brit. J Phar-macol. (1992) 105 (Suppl.):Abst. 116P.
   Google Scholar
• BELARDINELLI L eta].: A novel non-xanthine adenosine Ai receptor antagonist attenuates the negative dromo-tropic effects, but not coronary dilation, caused by adenosine and hypoxia in guinea pig hearts. Circula-tion (1990) 82(4, Suppl. 3):Abst 0594.
   Google Scholar
• XU J et al.: Role of adenosine signal transduction in global hypoxia-induced AV-nodal conduction block in the guinea-pig heart in vivo. FASEB J. 1992 (1992) 6 (4):Abst 1784.
   Google Scholar
• WESLEY RC, Jr. eta].: N0861: demonstration of selective Ai adenosine receptor antagonism in pigs. Cirailation (1990) 82(4, Suppl. 3):Abst 0595.
   Google Scholar
• SIDI A, WESLEY R, BARRETT R eta].: Cardiovascular ef-fects of a nonxanthine-selective antagonist of the Ai adenosine receptor in the anaethetised pig: pharma-cological and therapeutic implications. (1994) Cardio-vasc. Res. 28: 621–628.
   Google Scholar
• N-0861. Clin. Trials. Monitor. (1995) 4:34.
   Google Scholar
• SCHINGNITZ G et al.: Selective Ai antagonists for treat-ment of cognitive deficits. Nucleos. Nucleot. (1991) 10:1067.
   Web of Science ®Google Scholar
• KOGI K, UCHIBORI T, AIHARA K eta].: Pharmacological profile of the 2-alkynyladenosine derivative 2-octynyladenosine (YT-146) in the cardiovascular sys-tem. Japan. Pharmacol. (1991) 57:153–65.
   Google Scholar
• HUMPHRIES RG, ROBERTSON MJ, LEFF P: A novel series of P2Tpurinoceptor antagonists: definition of the role of ADP in arterial thrombosis. Trends Pharmacol. Sci. (1995) 16:179–181.
   PubMed Web of Science ®Google Scholar
• FRIZZELL RA: Functions of the cystic fibrosis trans-membrane conductance regulator protein. Am. J. Respir. Crit. Care. Med. (1995) 151 :S54–8.
   Web of Science ®Google Scholar
• TSUI LC: The cystic fibrosis transmembrane conduc-tance regulator gene. Am. j Respir. Crit. Care. Med. (1995) 151 :S47–53.
   PubMed Web of Science ®Google Scholar
• KNOWLES MR, OLIVIER K, NOONE P, BOUCHER RC: Pharmacologic modulation of salt and water in the air-way epithelium in cystic fibrosis. Am. J Respir. Crit. Care. Med. (1995) 151:S65–9.
   PubMed Web of Science ®Google Scholar
• BENNETT WD, OLIVIER KN, ZEMAN KL eta].: Effect of uridine 5'-triphosphate plus amiloride on mucociliary clearance in adult cystic fibrosis. Am. J Respir. Crit. Care. Med. (1996) 153:1796–801.
   Google Scholar
• RAPPAPORT E, FONTAINE J: Anticancer activites of ade-nine nucleotides in mice are mediated through expan-sion of erythrocyte ATP pools. PNAS (1989) 86:1662–1666.
   PubMed Web of Science ®Google Scholar
• HASKELL CM, WONG M, WILLIAMS A, LEE LY: Phase I trial of ex tracellular adenosine 5'-triphosphate in patients with advanced cancer. Med. Pediatr. Oncol. (1996) 27:165–173
   PubMedGoogle Scholar
• MENDOZA E, FOSELLA F, HASKELL C eta].: Adenosine tri-phosphate (ATP) for advanced non-small cell lung cancer (NSCLC): a Phase II multicenter study (Meeting abstract). Proc. Annu. Meet. Am. Soc. Clin. Oncol (1996) 15:A1238.
   Google Scholar
• BOHM M, WEINHOLD C, SCHWINGER RH eta].: Studies of the nucleoside transporter inhibitor, draflazine, in the human myocardium. Br. J. Pharmacol. (1994) 112:137–142.
   Google Scholar
• BEUKERS MW, KERKHOF CJ, IJZERMAN AP, SOUDINJN W: Nucleoside transport inhibition and platelet aggrega-tion in human blood: R75231 and its enantiomers, draflazine and R88016. Eur.J. Pharmacol. (1994) 266:57–62.
   PubMed Web of Science ®Google Scholar
• ANDERSEN K, DELLBORG M, SWEDBERG K: Nucleoside transport inhibition by draflazine in unstable coro-nary disease. Eur. Clin. Pharmacol. (1996) 51:7–13.
   Web of Science ®Google Scholar
• MANGANO DT, FOR THE MCSPI RESEARCH GROUP: H-fects of acadesine on myocardial infarction, stroke, and death following surgery. A meta-analysis of the five international randomized trials. JAMA (1997) 277:325–332.
   Google Scholar
• BULLOUGH DA, FOX MH, MULLANE KM: Acadesine regu-lates adenosine to improve post-ischaemic function in the isolated heart [abstract]. j MaCardiol(1992)24:S6.
   Google Scholar
• YOUNG MA, MULLANE KM: Progressive cardiac dys-function with repeated pacing-induced ischemia: pro-tection by AICA-riboside. Am. J. Physiol. (1991) 261:H1570–7.
   PubMed Web of Science ®Google Scholar
• HORI M, KITAKAZE M, TAKASHIMA S eta].: AICAriboside improves myocardial ischemia in coronary microem-bolization in dogs. Am. J Physiol. (1994) 267:H1483–95.
   Google Scholar
• BURCKHARTT B, YANG XM, TSUCHIDA A et al.: Acadesine extends the window of protection afforded by ischaemic preconditioning in conscious rabbits. Cardiovasc. Res. (1995) 29:653–657.
   PubMed Web of Science ®Google Scholar
• BOLLING SF, GROH MA, MATTSON AM et al.: Acadesine (AICA-riboside) improves post-ischemic cardiac re-covery. Ann. Thorac. Surg. (1992) 54:93–98.
   PubMed Web of Science ®Google Scholar
• GALINANES M, BULLOUGH D, MULLANE KM, HEARSE DJ: Sustained protection by acadesine against ischemia and reperfusion-induced injury: studies in the trans-planted rat heart. Cirailation (1992) 86:589–97.
   PubMed Web of Science ®Google Scholar
• MULTICENTER STUDY OF PERIOPERATIVE ISCHEMIA (MCSPI) RESEARCH GROUP: Effects of acadesine on the incidence of M1 and adverse cardiac outcomes after coronary artery bypass graft surgery. Anesthesiology (1995) 83:658–673.
   PubMed Web of Science ®Google Scholar
• MENASCHE P, JAMIESON WR, FLAMENG W, DAVIES MK: Acadesine: a new drug that may improve myocardial protection in coronary artery bypass grafting. Results of the first international multicenter study. Multinational Acadesine Study Group. J. Thorac. Cardio-vasc. Surg. (1995) 110:1096–106.
   Google Scholar
• MANGANO DT, FOR THE MCSPI RESEARCH GROUP: H-fects of acadesine on MI, stroke, and death following surgery. Anesth. Analg. (1996) 82 :SCA42.
   Google Scholar
• ERION MD, UGARKAR BG, DARE J eta].: Design, synthe-sis and anticonvulsant activity of the potent adenosine kinase inhibitor GP3269. Nucleos. Nucleot. (1997) 16:1013–1021.
   Google Scholar